1-(5-Bromo-6-methylpyridin-2-yl)piperazine hydrochloride

Catalog No. :
ACLGTU816
CAS No. :
1187386-04-4
Molecular Formula :
C10H15BrClN3
Molecular Weight :
292.61

IUPAC Name:1-(5-bromo-6-methylpyridin-2-yl)piperazine hydrochloride

1-(5-Bromo-6-methylpyridin-2-yl)piperazine hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g98%$58.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(5-Bromo-6-methylpyridin-2-yl)piperazine hydrochloride
IUPAC Name1-(5-bromo-6-methylpyridin-2-yl)piperazine hydrochloride
MDL No.MFCD12913993
Molecular FormulaC10H15BrClN3
Molecular Weight292.61
SMILESCC1=C(Br)C=CC(N2CCNCC2)=N1.[H]Cl
InChI KeyYDTHXIFPWDWGQJ-UHFFFAOYSA-N
Synonym1187386-04-4 | 1-(5-Bromo-6-methylpyridin-2-yl)piperazine hydrochloride | 3-Bromo-6-piperazinopicoline, HCl | 3-Bromo-6-piperazinopicoline hydrochloride | 1-(5-bromo-6-methylpyridin-2-yl)piperazine;hydrochloride | 1-(5-Bromo-6-methylpyridin-2-yl)piperazinehydrochlo
CAS No.1187386-04-4
PubChem CID46739819

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H317-H319
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACLGTU816 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. ACUMDW493 route compound structure diagram
    ACUMDW49339919-65-8 In Stock
  4. Then
  5. ACLGTU816 route product structure diagram
    ACLGTU8161187386-04-4
Inquiry

2. ACLGTU816 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. ACKLBZ206 route compound structure diagram
    ACKLBZ206375368-83-5 In Stock
  4. Then
  5. ACLGTU816 route product structure diagram
    ACLGTU8161187386-04-4
Inquiry

Comments (0)